• Publications
  • Influence
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
TLDR
In this first prospective study of modified FOLFIRINOX in MPC and LAPC, decreased AEs are observed compared with historical control patients and the efficacy appears comparable with FOL FIRINOX, and support the continued use of F OLFIRinoX in this setting.
Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.
TLDR
FOLFOX/CAPOX is proved effective for advanced SBA in this study, but the results do not absolutely agree with previous studies from Western countries, showing that further studies are still needed.
Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma
TLDR
The combination of capecitabine and cisplatin is active and well tolerated as a first-line therapy for patients with metastatic NPC.
EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients
  • Yu-hong Li, Fang Wang, +8 authors J. Shao
  • Biology, Medicine
    Clinical Cancer Research
  • 11 January 2011
TLDR
Patients with EGFR FISH pattern of chromosome 7 disomy may be as a negative predicative factor for cetuximab response in KRAS wild-type metastatic colorectal cancer patients.
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
TLDR
To determine the impact of attenuated doses of irinotecan and bolus 5FU on efficacy and tolerability, a prospective phase II study of modified FOLFIRINOX in advanced PC with pegylated filgrastim was conducted.
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma
TLDR
The results suggest that the addition of bevacizumab to mFOLFOX6 may provide clinical benefit in American patients with metastatic gastroesophageal adenocarcinoma, a finding consistent with previous studies of first-line bevazumab in combination with chemotherapy for this disease.
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
TLDR
As the first single-domain PD-L1-targeting antibody administered by rapid subcutaneous injection, envafolimab has the potential to be a significant advance in the treatment of cancer.
Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial
  • Fenghua Wang, G. Dai, +13 authors Ruihua Xu
  • Medicine
    Chinese journal of cancer research = Chung-kuo…
  • 31 August 2021
TLDR
This observational phase IV trial broadens the experience and knowledge of bevacizumab in the Chinese population and provides a good indication of its overall efficacy and safety.
Predictive Biomarkers and Personalized Medicine EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer
Purpose: Metastatic colorectal cancer patients with low epidermal growth factor receptor (EGFR) gene copy number are unlikely to respond to anti-EGFR monoclonal antibody (mAb) treatment. The
Efficacy and safety of rhLTα-Da with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-labelled, controlled, phase IIb trial.
TLDR
This randomized, multicenter, controlled, phase II b trial was conducted to evaluate the efficacy and safety of rhLTα-Da with cisplatin and fluorouracil as the first-line therapy for mESCC.
...
1
2
...